Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Institutional response to FDA warning on aprotinin and impact on outcomes.
2
Zitationen
8
Autoren
2009
Jahr
Abstract
In response to new data and regulatory guidelines, we formulated guidelines based on expert review of data. We reduced aprotinin use, but more importantly, introduced an evidence-based approach to the use of aprotinin, consistent with regulatory guidelines. This model of guideline implementation can be useful in similar scenarios.
Ähnliche Arbeiten
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 5.191 Zit.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 · 3.216 Zit.
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
2015 · 2.402 Zit.
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 2.044 Zit.
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
1987 · 2.019 Zit.